Strategic Growth Mainstay Medical is expanding its international footprint with subsidiaries in Ireland, the United States, Australia, Germany, and the Netherlands, presenting sales opportunities across Europe, North America, and APAC markets.

Clinical Leadership With the ReActiv8 restorative neurostimulation system already FDA approved and ongoing RESTORE trials, there is a strong clinician-led value proposition ripe for hospital systems and pain management centers seeking innovative chronic low back pain solutions.

Investment Momentum Recent $125 million equity financing and high-profile board additions signal strong investor confidence and resources to scale key accounts, distribution partnerships, and payer negotiations.

Revenue Potential Current revenue range of 25 to 50 million amid a targeted market for neuromodulation offers multiple entry points for mid-market hospitals and specialty clinics looking to expand chronic pain portfolios.

Strategic Partnerships Collaboration opportunities with large medical device players or distributors seeking to add neuromodulation capabilities, given competitors’ scale and Mainstay’s focused, FDA-approved technology.